Sua seleção (0)
Detalhe da pesquisa
1.
The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt.
Blood;
134(Supplement_1): 28, 2019 Nov 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31723981
2.
Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update.
Blood;
134(Supplement_1): 30, 2019 Nov 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31724000
3.
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
Blood;
132(4): 393-404, 2018 Jul 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-29567798
4.
Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.
Clin Cancer Res;
25(22): 6606-6613, 2019 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31292142
5.
Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome.
Br J Haematol;
187(3): 337-346, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31271217
6.
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.
Blood;
129(7): 846-854, 2017 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-27932374
7.
Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia.
Haematologica;
104(6): 1150-1155, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30573507
8.
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.
Cancer;
124(14): 2956-2963, 2018 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29723417
9.
How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.
Br J Haematol;
180(1): 24-32, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29048128
10.
Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia.
Haematologica;
2018 Aug 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30093398
11.
Treatment-free remission with first- and second-generation tyrosine kinase inhibitors.
Am J Hematol;
2018 Nov 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30394563
12.
Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.
Cancer;
123(22): 4403-4410, 2017 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28743166
13.
Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors.
Blood;
125(6): 901-6, 2015 Feb 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-25525119
14.
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia.
Blood;
125(3): 499-503, 2015 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25343957
15.
Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study.
Haematologica;
102(8): 1368-1377, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28522576
16.
Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib.
Blood;
124(5): 729-36, 2014 Jul 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-24948656
17.
Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
Am J Hematol;
91(9): 869-74, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27192969
18.
Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up.
Cancer;
121(10): 1637-44, 2015 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25586015
19.
Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia.
Ann Hematol;
94 Suppl 2: S149-58, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25814081
20.
Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome.
Eur J Haematol;
94(4): 363-7, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24797802